Golimumab for Type 1 Diabetes; Long-Term Success for Oral Octreotide

Subcutaneous treatment with the human monoclonal antibody golimumab (Simponi) helped kids and young adults newly diagnosed with type 1 diabetes use less insulin, according to a 52-week phase II study. (New England Journal of Medicine)

Oral octreotide (Mycapssa) was noninferior to long-acting injectables, maintaining IGF-1 response in 91% of patients with acromegaly over 9 months, Chiasma announced.

More evidence supporting the Mediterranean diet: a 20-year prospective study found adherence to this diet reduced women's risk of future diabetes by 30%. (JAMA Network Open)

People with diabetes or hypertension might be at a higher risk of neurological complications from COVID-19. (ScienceDaily)

Black and Hispanic children with type 1 diabetes were significantly less likely to start using a continuous glucose monitor (CGM), as well as more likely to discontinue using a CGM, than white children. (Diabetes Care)

Even people with well-controlled diabetes carry an excess risk for cardiovascular disease than someone free of diabetes. "People with type 2 diabetes should be treated for cardiovascular risk factors as early as possible, regardless of whether they have cardiovascular disease or not," said lead author Alison Wright, PhD, of the University of Manchester in England. (Circulation)

A balanced crystalloid solution resolved diabetic ketoacidosis on average 3.9 hours faster than saline for fluid therapy in the emergency department, an analysis of cluster randomized clinical trials found. (JAMA Network Open)

A small study of transgender patients with cancer found few oncologists discussed possible interactions between cancer treatment and gender-affirming care. (JAMA Oncology)

Comment